In 2017, Eurofins Scientific acquired Alphora Research Inc. to support Eurofins’ drug development platform. Starting in July, the commercial brand for Eurofins Alphora will be Eurofins CDMO (Contract Development Manufacturing Organization) falling under the CDMO umbrella in conjunction with Eurofins Amatsigroup. Eurofins CDMO will provide an integrated, end-to-end solution for Pre-Clinical and Clinical outsourcing services of both Drug Substance/API and Drug Product manufacturing for biologics and small molecules.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
Based on a statement from the company, this rebranding will:
- Support clients to move rapidly through the drug development value chain
- Perform complex formulation screening and development for sterile and non-sterile manufacturing
- Accelerate process development and scale-up under GMP compliance
- Supply clinical trial materials, including packaging and logistics
- Provide regulatory compliance throughout each stage of the development cycle
Eurofins Alphora provides API technology services for the scale-up of complex small molecules for pharmaceutical and biotechnology companies. The company provides flexible and sustainable solutions to support IND through to Commercial Readiness of APIs. Eurofins Alphora operates FDA and Health Canada inspected facilities including cGMP Plants, Organic Chemistry, PR&D, and Drug Product Development laboratories supported by Quality Control/Quality Assurance functions. A separate high-potency suite completes Alphora’s 74,000ft² facilities. A 3rd cGMP plant has recently come online to add additional capacity for an active pipeline of projects.